Literature DB >> 19483635

Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study.

Emanuela Veras1, Anais Malpica, Michael T Deavers, Elvio G Silva.   

Abstract

SUMMARY: The assessment of an accurate mitotic index (MI) is one of the major parameters in the proper classification of uterine smooth muscle tumors. This assessment can be hampered by the presence of increased number of apoptotic bodies or piknotic nuclei, which frequently mimic mitoses. Phospho-histone H3 (PHH3) is a recently described immunomarker specific for cells undergoing mitoses. In this study, we evaluated the MI of 2 subsets of uterine smooth muscle tumors--6 leiomyosarcomas (LMS) and 6 smooth muscle tumors of undetermined malignant potential (STUMP)--using PHH3-labeled sections and hematoxylin and eosin (H&E)-stained slides. In the STUMP group, the MI on H&E ranged from 0 to 9 mitoses/10 high-power fields (HPFs) (mean, 3.2), and in the LMS group, it ranged from 0 to 37 mitoses/10 HPFs (mean, 19). PHH3 showed 0 to 16 mitoses/10 HPFs (mean, 3.8) in the STUMP group and 0 to 61 mitoses/10 HPFs (mean, 26) in the LMS group. In 7 cases, the MI difference (MID) between H&E-stained and PHH3-stained slides varied from 0 to 3 mitoses (mean, 1.6). In only one LMS, the PHH3 MI was lower than on H&E-stained slides (MID 7). The MI on H&E-stained and PHH3-stained slides were comparable in 7 cases, 5 of which were STUMPs. In 4 other cases, 3 of which were LMS, the PHH3 MI was significantly higher than the one obtained on H&E. The higher MI obtained with PHH3-labeled sections in some cases is most likely due to the recognition of true mitoses by the antibody, which were initially misinterpreted as apoptotic bodies and/or piknotic nuclei on H&E and not included in the formal count, and the fact that the phosphorilation of histone H3 starts just before the prophase and at this stage mitoses cannot be identified by H&E.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19483635     DOI: 10.1097/PGP.0b013e318193df97

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  15 in total

1.  Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.

Authors:  Eleonora Duregon; Adele Cassenti; Alessandra Pittaro; Laura Ventura; Rebecca Senetta; Roberta Rudà; Paola Cassoni
Journal:  Neuro Oncol       Date:  2015-02-01       Impact factor: 12.300

2.  Generation and purification of highly specific antibodies for detecting post-translationally modified proteins in vivo.

Authors:  Swathi Arur; Tim Schedl
Journal:  Nat Protoc       Date:  2014-01-23       Impact factor: 13.491

3.  Phosphohistone H3: implications for clinical practice and risk assessment in meningioma.

Authors:  Adriana Olar
Journal:  Neuro Oncol       Date:  2015-03-25       Impact factor: 12.300

4.  Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors.

Authors:  Arnaud Uguen; Gwenaël Conq; Laurent Doucet; Matthieu Talagas; Sebastian Costa; Marc De Braekeleer; Pascale Marcorelles
Journal:  Virchows Arch       Date:  2015-04-01       Impact factor: 4.064

Review 5.  Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.

Authors:  Esther Oliva
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

6.  Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma.

Authors:  Adriana Olar; Khalida M Wani; Erik P Sulman; Alireza Mansouri; Gelareh Zadeh; Charmaine D Wilson; Franco DeMonte; Gregory N Fuller; Kenneth D Aldape
Journal:  Brain Pathol       Date:  2014-10-29       Impact factor: 6.508

7.  Value of counting positive PHH3 cells in the diagnosis of uterine smooth muscle tumors.

Authors:  Shu-Jie Pang; Cheng-Cheng Li; Yan Shen; Yian-Zhu Liu; Yi-Quan Shi; Yi-Xin Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

8.  Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma.

Authors:  Yun Liang; Xiaofei Zhang; Xiaoduan Chen; Weiguo Lü
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

9.  pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant.

Authors:  A Brunner; P Riss; G Heinze; H Brustmann
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

10.  PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors.

Authors:  Yooju Shin; Jiyeon Hyeon; Boram Lee; Sang Yun Ha; Min Eui Hong; In Gu Do; Kyoung-Mee Kim
Journal:  J Pathol Transl Med       Date:  2015-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.